The election was held prior to BioNJ’s 27th Annual Dinner Meeting and Innovation Celebration on Feb. 6.
“Because patients can’t wait, we are grateful for our talented and dedicated board and advisors whose guidance is invaluable to BioNJ’s mission of helping our members help patients,” said BioNJ President and CEO Debbie Hart. “We welcome back our notable list of returning officers, board members and advisors whose leadership has been instrumental in the work that we do and are thrilled to have the addition of four new board members and new academic and VC advisors who are accomplished and respected industry leaders. We look forward to working with all of them as we forge ahead ensuring that New Jersey remains a robust life sciences ecosystem and that patients have access to the right medicines at the right time,” said Hart.
All officers were re-elected to serve one-year terms: Chairman Christopher Schaber, president and chief executive officer, Soligenix; Vice Chairman Daniel O’Connor, president and CEO, OncoSec Medical; Treasurer Dr. Monika Vnuk, vice president, R&D Business Development, Pfizer; and Secretary Michele Korfin, chief operating officer, Tyme Technologies.
Newly elected board members are: Jayne Gershkowitz, chief patient advocate, Amicus Therapeutics; Will Lewis, chairman and CEO, Insmed; Jeffrey Nau, president and CEO, Oyster Point Pharma; Dr. Andrew Pecora, CEO Outcomes Matter Innovations; and Navneet Puri, founder, chairman and CEO, Nevakar.
Newly appointed advisors are: Academic Advisor Dr. Reynold Panettieri Jr., vice-chancellor, Translational Medicine and Science and Director, Rutgers Institute for Translational Medicine and Science, professor of Medicine, Rutgers University and emeritus professor of Medicine, University of Pennsylvania; and VC Advisor Jorge Ramirez, principal, H.I.G. BioHealth Partners.
Steven Cohen, partner, Morgan, Lewis & Bockius LLP, was re-appointed as BioNJ’s legal advisor.